Search

Quinfamide

Quinfamide has been used in trials studying the treatment of Amoebiasis and Helminthiasis.

Votucalis

rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

Darapladib

AD 337

The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients. … AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).

EP-2104R

It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.

Asciminib

[L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.

Ginkgolide A

Ginkgolide A is a highly active PAF antagonist cage molecule that is isolated from the leaves of the Ginkgo biloba tree. Shows potential in a wide variety of inflammatory and immunological disorders.

Glycyrrhiza glabra

Glycyrrhiza glabra is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Matrix-M

[L27981] This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines. … Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.

Gedatolisib

Celcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.